Subgroup Analysis Sample Clauses
Subgroup Analysis. Key efficacy and safety results will be summarized across subgroups defined by age group (3 – < 24 months, 2 years to 11 years, 12 to < 18 years).
Subgroup Analysis. The data was analyzed using various subgroups. After adjusting for age, gender, diagnosis, conditioning regimen, donor source and disease status, there was a consistent trend toward lower overall odds of developing OM and severe OM with the use of palifermin among various groups (Figure 3a and Figure 3b) aFBT: Fludarabine, busulfan and TBI, bCR: Complete remission. aFBT: Fludarabine, busulfan and TBI, bCR: Complete remission.